Canada Markets open in 3 hrs 48 mins

IVERIC bio, Inc. (ISEE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.62-1.56 (-9.64%)
At close: 04:00PM EST
14.62 0.00 (0.00%)
After hours: 04:40PM EST

IVERIC bio, Inc.

Five Penn Plaza
Suite 2372
New York, NY 10001
United States
212 845 8200

Full Time Employees66

Key Executives

NameTitlePayExercisedYear Born
Mr. Glenn P. Sblendorio M.B.A.CEO & Director1.25MN/A1956
Dr. Pravin U. Dugel M.D.Pres780.65kN/A1964
Mr. David F. CarrollSr. VP, CFO & Treasurer633.58kN/A1966
Mr. Keith Westby M.B.A.Sr. VP & COO621.22kN/A1975
Dr. Samir C. PatelCo-Founder and ConsultantN/AN/A1961
Dr. Xiao-Ping Dai Ph.D.Chief Technical OfficerN/AN/AN/A
Dr. Abraham Scaria Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Kathy GalanteSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Todd D.C. AndermanSr. VP, Gen. Counsel & Corp. Sec.N/AN/AN/A
Ms. Amy R. SheehanSr. VP & Chief HR OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.

Corporate Governance

IVERIC bio, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.